Oral glibenclamid ved for tidlig hyperglykæmi (GALOP) (GALOP)
The purpose of this study is to confirm hypothesis that Glibenclamide can be administered orally and is an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Transient hyperglycemia of premature newborns results from an overall decrease in insulin sensitivity, which is responsible at the beta cell level for abnormalities of intragranular cleavage of proinsulin into insulin, leading to reduced active insulin secretion. Intravenous administration of exogenous insulin can be used to combat insulin resistance and lower blood glucose, but it is difficult to manage in premature newborns and is associated with a substantial risk of hypoglycemia. Glibenclamide, which stimulates endogenous insulin secretion and can be administered orally, might be an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Paris, Frankrig, 75015
- Hopital Necker - Enfants malades
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Newborn less than 34 week of amenorrhea corrected age
- Birth weight < 1500 g
- Birth term < 32 week of amenorrhea
- Hyperglycemia ≥ 10 mmol/l in 2 measurements, 3 hours apart after potential reduction of glucose intakes following each department's protocol
- Secure venous access point (umbilical venous catheter or epicutaneo-cava catheter)
- Enteral feeding considered before inclusion or already established
- Consent obtained from persons holding parental authority
- Beneficiary of social security
Exclusion Criteria
- Contraindication to enteral feeding (at the discretion of the clinician responsible for the child)
- Contraindication to glibenclamide according to current SPC
- Foetal growth restriction (FGR) birth weight < 3rd percentile (AUDIPOG definition)
- Severe birth defect, including cardiac malformation associated with a risk of myocardial ischemia
- Severe sepsis requiring mechanical ventilation or haemodynamic support
- Severe renal dysfunction (serum creatinine > 120 µmol/l)
- Severe hepatocellular failure (V factor less than the standard laboratory range for the age) and/or severe cholestasis (> 50 µmol/L)
- Hyperglycemia associated with an error in administering glucose infusion
- Profound hypophosphoremia (< 1 mmol/l)
- Hypersensitivity to glibenclamide or other sulphonylureas or sulphonamides, or one of the excipients
- Patient with continuous insulin IV administration
- Patient treated with miconazole
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Glibenclamide oral
Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk |
Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant, apparent clearance and volume of distribution. blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio if it is impossible to collect both volumes, the C-peptide collection will be prioritized If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram, total bilirubin and conjugated bilirubin will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment. Transaminases and hemostasis will be done only in case of clinical indication before the first administration. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Blood glucose control
Tidsramme: At 72 hours after the first administration
|
The primary evaluation criteria is 72 hours blood glucose control on glibenclamide treatment (success of the treatment). This is defined as the non-use of insulin and absence of severe hypoglycemia (< 1.5 mmol/l) or persistent moderate hypoglycemia (< 2.6 mmol/l in 2 successive measurements (dextro) at an interval of more than 3 hours) |
At 72 hours after the first administration
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall success of the treatment
Tidsramme: At 36 week of amenorrhea corrected age
|
Overall success of the treatment defined by continuation to the end of treatment without recourse to insulin. |
At 36 week of amenorrhea corrected age
|
|
Blood glucose profile on glibenclamide
Tidsramme: At the end of treatment assessed up to 15 days
|
Time between the start of glibenclamide treatment and the 1st blood glucose < 10 mmol/l |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
Tidsramme: At the end of treatment assessed up to 15 days
|
Time between the start of glibenclamide treatment and the 1st blood glucose < 8 mmol/l |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
Tidsramme: At the end of treatment assessed up to 15 days
|
Proportion of time spent within the target blood glucose range (≥ 4 and < 10 mmol/l) during the period of glibenclamide treatment |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
Tidsramme: At the end of treatment assessed up to 15 days
|
Proportion of time spent above the target level (≥ 10 mmol/l) during the period of glibenclamide treatment |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
Tidsramme: At the end of treatment assessed up to 15 days
|
Proportion of time spent in hypoglycemia (< 2.6 mmol/l) during the period of glibenclamide treatment |
At the end of treatment assessed up to 15 days
|
|
Duration of glibenclamide treatment
Tidsramme: At the end of treatment assessed up to 15 days
|
Duration of glibenclamide treatment. |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth
Tidsramme: At the end of treatment assessed up to 15 days
|
Carbohydrate |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
Tidsramme: At the end of treatment assessed up to 15 days
|
lipid |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
Tidsramme: At the end of treatment assessed up to 15 days
|
protein |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
Tidsramme: At the end of treatment assessed up to 15 days
|
mean caloric intake (kcal/kg/day) during treatment |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
Tidsramme: At the end of treatment assessed up to 15 days
|
mean weight gain (g/kg/day) |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth
Tidsramme: At 36 week of amenorrhea corrected age
|
Carbohydrate |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
Tidsramme: At 36 week of amenorrhea corrected age
|
lipid |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
Tidsramme: At 36 week of amenorrhea corrected age
|
protein |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
Tidsramme: At 36 week of amenorrhea corrected age
|
mean caloric intake (kcal/kg/day) during treatment |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
Tidsramme: At 36 week of amenorrhea corrected age
|
mean weight gain ((g/kg/day) |
At 36 week of amenorrhea corrected age
|
|
Number of children with episode of hypoglycemia
Tidsramme: At 72 hours after first administration
|
Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia |
At 72 hours after first administration
|
|
Number of children with episode of hypoglycemia
Tidsramme: At the end of treatment assessed up to 15 days
|
Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia |
At the end of treatment assessed up to 15 days
|
|
Type of adverse reactions on glibenclamide
Tidsramme: At 36 week of amenorrhea corrected age
|
evaluation of the type of adverse reactions identified during the study |
At 36 week of amenorrhea corrected age
|
|
Number of adverse reactions on glibenclamide
Tidsramme: At 36 week of amenorrhea corrected age
|
evaluation of number of adverse reactions identified during the study |
At 36 week of amenorrhea corrected age
|
|
Number of participants with co-morbidity
Tidsramme: At 36 week of amenorrhea corrected age
|
Neonatal morbidity assessed at 36 WA corrected age: intraventricular haemorrhage, periventricular leukomalacia, retinopathy of premature newborns, haemodynamic disorders, ulcerative necrotising enterocolitis |
At 36 week of amenorrhea corrected age
|
|
Mortality
Tidsramme: At 36 week of amenorrhea corrected age
|
Mortality will be assessed |
At 36 week of amenorrhea corrected age
|
|
Dose adjustment
Tidsramme: At the end of treatment assessed up to 15 days
|
Number of dose adjustments, to evaluate the easy of use |
At the end of treatment assessed up to 15 days
|
|
ease of use by caregivers
Tidsramme: At day one of treatment
|
Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score |
At day one of treatment
|
|
ease of use by caregivers
Tidsramme: At day two of treatment
|
Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score |
At day two of treatment
|
|
ease of use by caregivers
Tidsramme: At day three of treatment
|
Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score |
At day three of treatment
|
|
Plasma concentrations of glibenclamide
Tidsramme: At 3 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 3 hours after the first administration
|
|
Plasma concentrations of glibenclamide
Tidsramme: At 6 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 6 hours after the first administration
|
|
Plasma concentrations of glibenclamide
Tidsramme: At 10 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 10 hours after the first administration
|
|
Plasma concentrations of glibenclamide
Tidsramme: At 24 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 24 hours after the first administration
|
|
Plasma concentrations of glibenclamide
Tidsramme: At 24 hours of blood glucose stabilization
|
Evaluated by the pharmacokinetics study |
At 24 hours of blood glucose stabilization
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Studieleder: Jacques BELTRAND, Pr, Assistance Publique - Hôpitaux de Paris
- Studieleder: Michel POLAK, Assistance Publique - Hôpitaux de Paris
- Studieleder: Delphine MITANCHEZ, CHRU de Tours
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Metaboliske sygdomme
- Obstetrisk arbejde, for tidligt
- Obstetriske arbejdskomplikationer
- Graviditetskomplikationer
- Glukosemetabolismeforstyrrelser
- Ernæringsmæssige og metaboliske sygdomme
- For tidlig fødsel
- Hypoglykæmi
- Svovlforbindelser
- Organiske kemikalier
- Amider
- Sulfoner
- Urea
- Sulfonyluraforbindelser
- Glyburide
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- P160916J
- 2021-005766-18 (EudraCT nummer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .